Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 studyHongnan Mo, Binghe Xu, Dawei Wu et al.|British Journal of Cancer|2018Cited by 156
Promising efficacy of SHR‐1210, a novel anti–programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in ChinaJing Huang, Binghe Xu, Hongnan Mo et al.|Cancer|2018Cited by 66